Trial Profile

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jul 2025 Planned End Date changed from 31 Oct 2026 to 30 Apr 2027.
23 Jul 2025 Planned primary completion date changed from 31 Oct 2025 to 30 Apr 2026.
06 Jan 2025 According to an Amgen media release, announced that the UKs Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorization to IMDYLLTRA for the treatment of adult patients with extensive stage small cell lung cancer based on results from the Phase 2 open label, multicentre study DeLLphi-301.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com